Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
ECHELON-2: BV-CHP boosts survival in PTCL
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
News
Phase 3 data support apixaban for cancer-associated VTE
The rate of major bleeding was similar with apixaban and dalteparin.
News
FDA warns of serious side effect of AML treatment
Differentiation syndrome may be overlooked in AML patients taking enasidenib (Idhifa).
News
FDA approves gilteritinib for AML with FLT3 mutation
The approval is based on results from the ADMIRAL trial.
News
FDA approves rituximab biosimilar for lymphoma
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.
News
FDA approves glasdegib for AML
The U.S. Food and Drug Administration has approved the hedgehog pathway inhibitor glasdegib (Daurismo) for use in combination with low-dose...
News
Venetoclax gets accelerated approval in older AML patients
Venetoclax is approved in combination with azacitidine, decitabine, or low-dose cytarabine for certain AML patients.
News
FDA approves emapalumab for primary HLH
Emapalumab (Gamifant) is expected to be available in the U.S. in the first quarter of 2019.
News
Risk score can predict thrombosis in ITP
The researchers advised that risk should be reevaluated frequently as treatment is given.
News
Adjunctive Promacta approved for first-line SAA
Among the patients treated at the recommended dosing schedule, the 6-month overall response rate was 79%, and the complete response rate was 44...
News
Azacitidine-nivolumab combo 'encouraging' in AML
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
News
FDA clears new blood typing, screening instrument
The FDA has cleared NEO Iris, an automated blood bank instrument for mid- to high-volume labs.
News
Denosumab effective against osteoporosis in TDT patients
Denosumab increased bone density, reduced pain, and decreased markers of bone remodeling in patients with transfusion-dependent thalassemia.
News
FDA puts selinexor on fast track for DLBCL
Selinexor has received fast track designation to treat patients with previously treated DLBCL who are not eligible for certain therapies.
News
Portable hematology analyzer gets FDA nod
The HemoScreen hematology analyzer can perform a complete blood count at the point of care.